10 Battered Biotech Stocks That Hit 52-Week Lows Friday

Immune Design Corp (NASDAQ:IMDZ) slid to its 52-week low of $6.64 on Friday and has shed 66% of its value this year. The stock was in the portfolios of six of the hedge funds tracked by Insider Monkey on March 31, who collectively owned 7.10% of its shares.

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) hit a 52-week low of $3.34 on Friday before a late surge pushed it back up to $3.69. A position in the developer of compounded therapeutics was added to the portfolio of Bruce J. Richards and Louis Hanover’s Marathon Asset Management during the first quarter.

Intellia Therapeutics Inc (NASDAQ:NTLA) shares hit a new low on Friday and are trending down even further in morning trading on Monday, touching an all-time low of $17.12. It’s been an unsuccessful 2-month run for the company since its IPO in early May, as shares have fallen by 22%, including a 36% drop in the last month.

Mirati Therapeutics Inc. (NASDAQ:MRTX) ranked as one of hedge funds’ favorite stocks with an RSI under 30 a week ago, with its 14-Day RSI standing at 5.58 at that time. However, it has thus far failed to deliver a rebound, touching its 52-week low of $5.08 on Friday. Shares have gained 3.34% today.

Synergy Pharmaceuticals Inc (NASDAQ:SGYPW) hit a 52-week low of $0.35 on Friday after the company reported an update on its trials for plecanatide, including the resumption of patient enrollment in two phase III trials of the treatment. Shares have been battered to the tune of a 79% loss in 2016.

Lastly is Syros Pharmaceuticals Inc (NASDAQ:SYRS), which fell to a 52-week low of $14.27 on Friday and has already pushed that as low as $12.60 in morning trading today. Syros has proven to be another disappointing biotech IPO, having lost 23% since it went public at the end of June.

Disclosure: None